Scientists test Immune-Boosting drug with standard cancer treatments
NCT ID NCT02402920
Summary
This early-stage trial tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy and radiation could be a better treatment for small cell lung cancer. The study involved 83 patients and focused on finding safe doses and understanding side effects. Researchers wanted to see if this combination could help the body's immune system fight the cancer more effectively.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.